Phase II study of weekly irinotecan and cisplatin for refractory or recurrent non-small cell lung cancer

Lung Cancer

Volumn 58, Issue 2, 2007, Pages 253-259

  Takiguchi, Yuichi ^a   Moriya, Tetsuro ^a,b   Asaka Amano, Yoshiko ^a   Kawashima, Tatsuo ^c   Kurosu, Katsushi ^a   Tada, Yuji ^a   Nagao, Keiichi ^a   Kuriyama, Takayuki ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Matsudo City Hospital   (Japan)

^c TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

Author keywords

Cisplatin; Irinotecan; Non small cell lung cancer; Phase II study; Second line therapy

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG TOXICITY; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL;

EID: 34848839296     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.06.004     Document Type: Article

References (31)

1. Socinski M.A., Morris D.E., Masters G.A., and Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 123 (2003) 226S-243S
2. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 353 (2005) 123-132
3. Herbst R.S., Johnson D.H., Mininberg E., Carbone D.P., Henderson T., Kim E.S., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 (2005) 2544-2555
4. Georgoulias V.A. Second-line chemotherapy in relapsing or refractory patients with non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 38 Suppl 3 (2002) S61-S66
5. Huisman C., Smit E.F., Giaccone G., and Postmus P.E. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 18 (2000) 3722-3730
6. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
7. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
8. Fukuoka M., Niitani H., Suzuki A., Motomiya M., Hasegawa K., Nishiwaki Y., et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10 (1992) 16-20
9. Fukuoka M., and Masuda N. Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother Pharmacol 34 (1994) S105-S111
10. Rothenberg M.L. CPT-11: an original spectrum of clinical activity. Semin Oncol 23 (1996) 21-26
11. Devore III R., Johnson D., Crawford J., Dimery I., Eckardt J., and Eckhardt S.G. Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. Oncology 12 (1998) 79-83
12. Masuda N., Fukuoka M., Fujita A., Kurita Y., Tsuchiya S., Nagao K., et al. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br J Cancer 78 (1998) 251-256
13. Adjei A.A., Argiris A., and Murren J.R. Docetaxel and irinotecan alone and in combination, in the treatment of non-small cell lung cancer. Semin Oncol 26 (1999) 32-40
14. DeVore R.F., Johnson D.H., Crawford J., Garst J., Dimery I.W., Eckardt J., et al. Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 17 (1999) 2710-2720
15. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
16. Ferrigno D., and Buccheri G. Weekly chemotherapy with cisplatin and paclitaxel in inoperable non-small cell lung cancer: an extended phase II study. Anticancer Res 25 (2005) 4685-4692
17. Berardi R., Porfiri E., Scartozzi M., Lippe P., Silva R.R., Nacciarriti D., et al. Elderly patients with advanced non-small cell lung cancer. A phase II study with weekly cisplatin and gemcitabine. Oncology 65 (2003) 198-203
18. Kim S.-W., Suh C., Lee S.D., Kim W.S., Kim D.S., Kim W.D., et al. Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 41 (2003) 221-226
19. Nakanishi Y., Takayama K., Takano K., Inoue K., Osaki S., Wataya H., et al. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer. Am J Clin Oncol 22 (1999) 399-402
20. Kakolyris S., Kouroussis C., Souglakos J., Agelaki S., Kalbakis K., Vardakis N., et al. Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands) 34 Suppl 4 (2001) S71-S76
21. Georgoulias V., Agelidou A., Syrigos K., Rapti A., Agelidou M., Nikolakopoulos J., et al. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. Br J Cancer 93 (2005) 763-769
22. Negoro S., Fukuoka M., Niitani H., Suzuki A., Nakabayashi T., Kimura M., et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. CPT-11 Cooperative Study Group (in Japanese, with English abstract). Gan To Kagaku Ryoho 18 (1991) 1013-1019
23. Nakai H., Fukuoka M., Furuse K., Nakao I., Yoshimori K., Ogura T., et al. An early phase II study of CPT-11 in primary lung cancer (in Japanese, with English abstract). Gan To Kagaku Ryoho 18 (1991) 607-612
24. Pectasides D., Fountzilas G., Rigopoulos A., Bountouroglou N.G., Koutras A., Glotsos J., et al. Irinotecan and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. A phase II study of the Hellenic Cooperative Oncology Group. Anticancer Res 22 (2002) 3501-3506
25. Gonzalez Cao M., Aramendia J.M., Salgado E., Aristu J., Martinez Monje R., Algarra S.M., et al. Second-line chemotherapy with irinotecan and vinorelbine in stage IIIB and IV non-small-cell lung cancer: a phase II study. Am J Clin Oncol 25 (2002) 480-484
26. Font A., Sanchez J.M., Taron M., Martinez-Balibrea E., Sanchez J.J., Manzano J.L., et al. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism. Invest New Drugs 21 (2003) 435-443
27. Pectasides D., Mylonakis N., Farmakis D., Nikolaou M., Koumpou M., Katselis I., et al. Irinotecan and gemcitabine in patients with advanced non-small cell lung cancer, previously treated with cisplatin-based chemotherapy. A phase II study. Anticancer Res 23 (2003) 4205-4211
28. Han J.-Y., Lee D.H., Kim H.Y., Kim E.-A., Lee J.J., Ju S.Y., et al. A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. Clin Cancer Res 9 (2003) 5909-5914
29. Georgoulias V., Kouroussis C., Agelidou A., Boukovinas I., Palamidas P., Stavrinidis E., et al. Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study. Br J Cancer 91 (2004) 482-488
30. Wachters F.M., Groen H.J.M., Biesma B., Schramel F.M.N.H., Postmus P.E., Stigt J.A., et al. A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment. Br J Cancer 92 (2005) 15-20
31. Pectasides D., Pectasides M., Farmakis D., Kostopoulou V., Nikolaou M., Gaglia A., et al. Comparison of docetaxel and docetaxel-irinotecan combination as second-line chemotherapy in advanced non-small-cell lung cancer: a randomized phase II trial. Ann Oncol 16 (2005) 294-299